Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies

Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies

BackgroundCombined immunotherapy has shown promising results in the treatment of advanced HCC, whereas the priority population that would respond to the combined immunotherapy is still elusive. In addition, HCC with asymptomatic hyperamylasemia was not reported previously.Case presentationAn aged pa...

Full description

Bibliographic Details
Main Authors: Han Gao, Rui-zhi Chang, Xiao-ping Chen, Wan-guang Zhang, Bixiang Zhang, Xin Luo, Ze-yang Ding
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Immunology
Subjects:
hepatocellular carcinoma
asymptomatic hyperamylasemia
PD-1 inhibitor
CTLA-4 inhibitor
combined immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274449/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274449/full

Similar Items